Pharmacopeia, Inc. (NASDAQ: PCOP), a clinical development stage biopharmaceutical company, is focused on discovering and developing innovative small molecule therapeutics to attend to significant medical needs. The company’s broad portfolio of clinical and preclinical candidates are currently under development internally or with partners, including nine clinical compounds in Phase 2 or Phase 1 development. For further information, visit the Company’s web site at www.pcop.com.
- 17 years ago
QualityStocks
Pharmacopeia, Inc. (NASDAQ: PCOP)
Tags Rodman & Renshaw
Related Post
-
Silvercorp Metals Inc. (NYSE-A/TSX: SVM) Added to S&P/TSX Composite Index After a Year of Growth
Disseminated on behalf of Silvercorp Metals Inc. (NYSE-A/TSX: SVM) and includes paid advertisement. Analysts remain…
-
LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) Expands LIFE Investment Opportunity Amid Ramp-up to Abitibi Belt Production
Disseminated on behalf of LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) and may include…
-
QualityStocksNewsBreaks – Golden Triangle Ventures Inc. (OTC: GTVH) Establishes Snapt Beverages as Vertically Integrated Manufacturing and Brand Platform
Golden Triangle Ventures (OTC: GTVH) (“GTV”) announced the establishment of Snapt Beverages as its manufacturing and…